Growing Pipeline of ADC Candidates for Various Cancer Indications is Driving the IndustryDublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market - Global Industry Size, Share, ...

CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage ...

Lotte Biologics, the biotech arm of Lotte Group, said on Thursday it has signed a deal with an Asia-based biotech company for ...

Duchenne muscular dystrophy (DMD) is a devastating genetic disorder affecting approximately 1 in 3,500-5,000 newborn males worldwide. It is characterized by progressive degeneration of skeletal, ...

Antibody drug conjugates (ADCs) represent a revolutionary class of therapeutics, blending precision targeting with potent ...

Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironm ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

and TAIPEI, April 21, 2025 /PRNewswire/ -- Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C ...

Search for other works by this author on: ...

Seoul, April 24 Lotte Biologics, the biotech arm of Lotte Group, said on Thursday it has signed a deal with an Asia-based biotech company for the production of a clinical-stage antibody-drug conjugate ...

Additionally, in the framework of a licensing agreement and a collaborative endeavor to support innovative research, Debiopharm and Oncodesign Services will present promising new data illustrating how ...